Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein is a research paper published in Clinical Infectious Diseases (2020). On theSindex it has a DataRank of 1.2. It has been cited 35 times, with 23 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.538
From this paper's citation signal
Citation Network Contribution
0.692
From 21 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 23 citers.
NIH
Grant: UM1 AI068614
NIH
Grant: UM1 AI068618
NIH
Grant: UM1 AI068635
NIH
Grant: UM1 AI069453
NIH
Grant: UM1 AI069422
NIH
Grant: UM1 AI108568
NIH
Grant: UM1 AI069423
NIH
Grant: HHSN272201300033C
NIH
Grant: HHSN272201600012C
Bill & Melinda Gates Foundation
Grant: OPP1110830
Bill & Melinda Gates Foundation
Grant: OPP1017604
Collaboration of AIDS Vaccine Discovery of the Bill & Melinda Gates Foundation
Grant: OPP52845
NIAID NIH HHS
Grant: UM1 AI069452
NIMH NIH HHS
Grant: R21 MH083308
NIAID NIH HHS
Grant: U01 AI068614
NIAID NIH HHS
Grant: UM1 AI154463
NIAID NIH HHS
Grant: UM1 AI069481
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 3UM1AI108568-11S1
The Military HIV Research Program (MHRP) Clinical Trial Unit
National Institutes of Health
Grant: 4UM1AI069453-07
Soweto Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 5UM1AI069422-13
South African Medical Research Council Clinical Trials Unit (MRC CTU)
National Institutes of Health
Grant: 5UM1AI069423-18
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
NIAID
Novartis Vaccines and Diagnostics
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals